Mazdutide Shows Weight Reductions for Patients With Obesity

Newly published results from the GLORY-2 (NCT06164873) phase 3 randomized clinical trial reveal that a once-weekly 9-mg dose of mazdutide provided clinically meaningful weight reduction in Chinese adults with moderate to severe obesity. Over a 60-week treatment period, participants receiving the 9-mg dose achieved a mean weight reduction of 16.65%, a contrast to the 1.50% reduction observed in the placebo group. For pharmacists, this synthetic peptide analog of mammalian oxyntomodulin represents a next-generation therapeutic option that targets both appetite regulation and energy expenditure.¹

About The Findings

The mechanism of action is particularly relevant for clinical pharmacy, as mazdutide functions as a dual agonist to balance metabolic pathways. Although the glucagon-like peptide-1 (GLP-1) receptor agonism promotes satiety, reduces dietary intake, and stimulates insulin secretion, the activation of the glucagon receptor is expected to increase energy expenditure and improve hepatic fat metabolism.^2,3

This dual-pathway approach allows the drug to counteract potential hyperglycemia caused by glucagon receptor stimulation by balancing it with GLP-1 activation, effectively preserving beneficial effects on hemoglobin A_1C and weight loss. Systematic reviews have confirmed that this combined efficacy extends beyond weight loss, showing significant improvements in systolic and diastolic blood pressure, total cholesterol, and triglycerides.³

In the GLORY-2 trial, treatment was initiated at 3 mg once weekly and increased by 3 mg every 4 weeks until the maintenance dose of 9 mg was reached at week 8. This gradual escalation is designed to mitigate the gastrointestinal (GI) adverse reactions that are common with this class of medication. Clinical data indicates that vomiting, nausea, and diarrhea are the most frequently reported adverse effects, occurring in 53.1%, 46.9%, and 39.4% of the 9-mg dose group, respectively. Although these events are typically mild to moderate and transient, they mostly occur during the dose-escalation phase, requiring careful patient counseling on adherence and symptomatic management.¹

Findings Beyond Weight Management

The impact of mazdutide on patients with type 2 diabetes is another area for pharmaceutical oversight. Evidence from the GLORY-2 trial and previous meta-analyses suggests that although mazdutide remains effective for weight loss in diabetic populations, the magnitude of reduction is often less pronounced than in nondiabetic individuals. Specifically, participants with diabetes in the 9-mg group saw a 10.71% decrease in body weight, which, although lower than those who were not diabetic, was still associated with clinically meaningful improvements in glycemic control, including significant reductions in fasting plasma glucose and A_1C levels.^1,3

Furthermore, mazdutide has demonstrated a favorable safety profile regarding hypoglycemia, which did not show a statistically significant increase compared to placebo, offering a distinct advantage for diabetic patients with multiple comorbidities.³

Beyond weight and glucose metrics, mazdutide delivers comprehensive metabolic benefits that can simplify the management of obesity-related conditions. In participants with liver steatosis, the 9-mg dose reduced liver fat content by more than 60% at week 60, with over half of the participants achieving normalization of liver fat levels. However, pharmacists should monitor vital signs, as clinical studies have noted a transient increase in heart rate. In the 9-mg trial, the mean increase peaked at 7.1 beats per minute during titration before declining to 2.6 beats per minute by week 60.^1-3

READ MORE: Obesity Management Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. Published online June 07, 2026. doi:10.1001/jama.2026.8142

2. Innovent announces mazdutide, first dual GCG/GLP-1 receptor agonist, received approval from China's NMPA for chronic weight management. News release. June 27, 2025. Accessed June 8, 2026. https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html

3. Nalisa DL, Cuboia N, Dyab E, et al. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2024;15:1309118. Published 2024 Feb 14. doi:10.3389/fendo.2024.1309118